Therapeutic approaches targeting the polyamine pathway may therefore provide an effective strategy for the treatment of high risk neuroblastoma, particularly in tumors dependent on deregulated Myc activity, such as those with MYCN amplification. Here, MYCN is linked to neuroblastoma.